Wave Life Sciences, Inc.

Stage 4 · Declining · week 25

As of Oct 22, 2026, Wave Life Sciences is in Stage 4, the downtrend phase, now in week 25 (since Apr 30, 2026). It closed at $3.35, 84.3% below its 52-week high and below its 200-day average, which is falling.

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. More about the company

$3.35

-0.03% today

$660M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is WVE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 15w

S2 18w

S4 25w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 4w → S2 13w → S3 9w → S4 4w → S1 1w → S2 15w → S3 2w → S2 5w → S3 4w → S2 18w → S3 12w → S4 12w → S1 12w → S4 10w → S1 1w → S2 13w → S3 7w → S4 25w current

Total tracked: 165 weeks across 18 stage runs.

WVE among Biotechnology385th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…385	WVEWave Life Sciences, Inc.	Stage 4 · wk 25	20	−15.2%

vs 52W High

-84.3%

$3.09 lo$21.31 hi

84.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 25

1w13w26w

Week 25, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-56.8%

200 DMA: $7.75 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.56x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-15.2%

-42.3%

-54.2%

YTD

-79.0%

-57.3%

Scan Membership

Breakout Watch

Latest: 2024-09-13

10 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 25 · Vol 0.56x

2026-10-21S4

Wk 25 · Vol 0.55x

2026-10-20S4

Wk 24 · Vol 1.07x

2026-10-19S4

Wk 24 · Vol 0.54x

2026-10-16S4

Wk 24 · Vol 0.96x

2026-10-15S4

Wk 24 · Vol 0.99x

2026-10-14S4

Wk 24 · Vol 0.84x

2026-10-13S4

Wk 23 · Vol 1.25x

2026-10-12S4

Wk 23 · Vol 0.67x

2026-10-09S4

Wk 23 · Vol 0.49x

2026-10-08S4

Wk 23 · Vol 0.79x

2026-10-07S4

Wk 23 · Vol 0.91x

Moving averages & range

50 DMA

$4.28

200 DMA

$7.75

52W High

$21.31

52W Low

$3.09

5D Low

$3.13

Resistance levels (recent highs)

20d High

$3.88

60d High

$6.10

120d High

$7.47

250d High

$21.31

Next resistance

+15.8%

to 20d High

ROE

-67.4%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.4

Wave Life Sciences: quick answers

What stage is Wave Life Sciences in?

As of Oct 22, 2026, Wave Life Sciences (WVE) is in Stage 4, the downtrend phase. It entered Stage 4 on Apr 30, 2026 and is in week 25. What the four stages mean

Is Wave Life Sciences in an uptrend?

No. Wave Life Sciences is in a Stage 4 downtrend. It trades 56.8% below its 200-day average, which is falling.

How far is Wave Life Sciences from its 52-week high?

Wave Life Sciences closed at $3.35 on Oct 22, 2026, 84.3% below its 52-week high of $21.31. Its 52-week low is $3.09.

How has Wave Life Sciences performed over the past year?

As of Oct 22, 2026, Wave Life Sciences is down 57.3% over the past year and down 79.0% so far in 2026.

Which sector and industry is Wave Life Sciences in?

Wave Life Sciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.